Heron Therapeutics, Inc. stock is up 78.67% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.
Heron Therapeutics, Inc. engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy.